Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Avanos Medical, Inc. · 10-Q · Q1 FY2026 · Period ended Mar 31, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There have been no material changes regarding our market risk position from the information provided under Item 7A – “Quantitative and Qualitative Disclosures About Market Risk” in the Form 10-K. 29 Table of Contents